The fight against drug-re­sis­tant bac­te­ria march­es for­ward as Adap­tive Phage earns $40M+ Se­ries B

A com­pa­ny work­ing to­ward the field of bac­te­rio­phages, de­vel­op­ing ther­a­pies that use bac­te­ria-killing virus­es, just pulled in a sig­nif­i­cant amount of new cap­i­tal.

Adap­tive Phage Ther­a­peu­tics closed a $40.75 mil­lion Se­ries B, the Gaithers­burg, MD-based biotech an­nounced Tues­day morn­ing. The fi­nanc­ing was led by Deer­field Man­age­ment with par­tic­i­pa­tion from the Mayo Clin­ic, which had been a pre­vi­ous in­vestor.

Bac­te­rio­phages had long been an emp­ty area of re­search in the US, but the field has gar­nered more in­ter­est re­cent­ly as an­tibi­ot­ic-re­sis­tant bac­te­ria con­tin­ue to grow in promi­nence. Some of the ear­li­est sci­en­tists to the­o­rize about their use have thought that find­ing the right phages can lead to bet­ter treat­ments for in­fec­tions and ill­ness­es.

The mol­e­cules are virus­es, and work the same way hu­man-in­fect­ing virus­es do — by en­ter­ing host cells and repli­cat­ing. But in this case the host cells are bac­te­ria. The ul­ti­mate goal of bac­te­rio­phage ther­a­py is to use phages to en­ter bac­te­r­i­al cells and cause them to burst, there­by cur­ing pa­tients.

It’s long proved a dif­fi­cult task, name­ly due to the lack of re­search and fund­ing which is fail­ing to help prove these the­o­ries. Many of the pa­tients who have re­ceived ex­per­i­men­tal bac­te­rio­phage ther­a­pies have al­so been ex­treme­ly sick, with the treat­ments used as last-re­sort op­tions.

Fur­ther­more, there’s the need to iden­ti­fy specif­i­cal­ly which bac­te­r­i­al strain is in­fect­ing pa­tients, and match­ing the right bac­te­rio­phage to the pathogen. Mis­match­ing the two not on­ly won’t help the sick pa­tients, but might end up caus­ing fur­ther harm as well.

For Adap­tive Phage, the funds will go to­ward the ther­a­pies that come out of its pro­pri­etary plat­form. The com­pa­ny is de­vel­op­ing a bank of phages, say­ing it’s col­lect­ed hun­dreds of dif­fer­ent virus­es so far that pro­vide broad cov­er­age against six high-pri­or­i­ty, drug-re­sis­tant bac­te­ria.

Adap­tive Phage’s two lead pro­grams are to treat pros­thet­ic joint in­fec­tion and di­a­bet­ic foot os­teomyelitis, and they al­so plan to use some funds to ad­vance a sus­cep­ti­bil­i­ty test to more quick­ly iden­ti­fy po­ten­tial phage ther­a­pies. The com­pa­ny’s tech­nol­o­gy was orig­i­nal­ly de­vel­oped by the Pen­ta­gon’s biode­fense pro­gram, and Adap­tive Phage ac­quired it in 2017.

Deer­field is no stranger to this area ei­ther, as it bought out Melin­ta in March 2020 af­ter the an­tibi­otics com­pa­ny filed for Chap­ter 11 bank­rupt­cy. The deal turned over con­trol to Deer­field in ex­change for the $140 mil­lion of se­nior debt it holds in the com­pa­ny.

So­cial: Greg Mer­ril, Adap­tive Phage Ther­a­peu­tics CEO (Adap­tive Phage)

Health­care Dis­par­i­ties and Sick­le Cell Dis­ease

In the complicated U.S. healthcare system, navigating a serious illness such as cancer or heart disease can be remarkably challenging for patients and caregivers. When that illness is classified as a rare disease, those challenges can become even more acute. And when that rare disease occurs in a population that experiences health disparities, such as people with sickle cell disease (SCD) who are primarily Black and Latino, challenges can become almost insurmountable.

David Meek, new Mirati CEO (Marlene Awaad/Bloomberg via Getty Images)

Fresh off Fer­Gene's melt­down, David Meek takes over at Mi­rati with lead KRAS drug rac­ing to an ap­proval

In the insular world of biotech, a spectacular failure can sometimes stay on any executive’s record for a long time. But for David Meek, the man at the helm of FerGene’s recent implosion, two questionable exits made way for what could be an excellent rebound.

Meek, most recently FerGene’s CEO and a past head at Ipsen, has become CEO at Mirati Therapeutics, taking the reins from founding CEO Charles Baum, who will step over into the role of president and head of R&D, according to a release.

Jacob Van Naarden (Eli Lilly)

Ex­clu­sives: Eli Lil­ly out to crash the megablock­buster PD-(L)1 par­ty with 'dis­rup­tive' pric­ing; re­veals can­cer biotech buy­out

It’s taken 7 years, but Eli Lilly is promising to finally start hammering the small and affluent PD-(L)1 club with a “disruptive” pricing strategy for their checkpoint therapy allied with China’s Innovent.

Lilly in-licensed global rights to sintilimab a year ago, building on the China alliance they have with Innovent. That cost the pharma giant $200 million in cash upfront, which they plan to capitalize on now with a long-awaited plan to bust up the high-price market in lung cancer and other cancers that have created a market worth tens of billions of dollars.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Jay Bradner (Jeff Rumans for Endpoints News)

Div­ing deep­er in­to in­her­it­ed reti­nal dis­or­ders, No­var­tis gob­bles up an­oth­er bite-sized op­to­ge­net­ics biotech

Right about a year ago, a Novartis team led by Jay Bradner and Cynthia Grosskreutz at NIBR swooped in to scoop up a Cambridge, MA-based opthalmology gene therapy company called Vedere. Their focus was on a rather narrow market niche: inherited retinal dystrophies that include a wide range of genetic retinal disorders marked by the loss of photoreceptor cells and progressive vision loss.

But that was just the first deal that whet their appetite.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 117,700+ biopharma pros reading Endpoints daily — and it's free.

Rafaèle Tordjman (Jeito Capital)

Con­ti­nu­ity and di­ver­si­ty: Rafaèle Tord­j­man's women-led VC firm tops out first fund at $630M

For a first-time fund, Jeito Capital talks a lot about continuity.

Rafaèle Tordjman had spotlighted that concept ever since she started building the firm in 2018, promising to go the extra mile(s) with biotech entrepreneurs while pushing them to reach patients faster.

Coincidentally, the lack of continuity was one of the sore spots listed in a report about the European healthcare sector published that same year by the European Investment Bank — whose fund is one of the LPs, alongside the American pension fund Teacher Retirement System of Texas and Singapore’s Temasek, to help Jeito close its first fund at $630 million (€534 million). As previously reported, Sanofi had chimed in €50 million, marking its first investment in a French life sciences fund.

FDA hands ac­cel­er­at­ed nod to Seagen, Gen­mab's so­lo ADC in cer­vi­cal can­cer, but com­bo stud­ies look even more promis­ing

Biopharma’s resident antibody-drug conjugate expert Seagen has scored a clutch of oncology approvals in recent years, finding gold in what are known as “third-gen” ADCs. Now, another of their partnered conjugates is ready for prime time.

The FDA on Monday handed an accelerated approval to Seagen and Genmab’s Tivdak (tisotumab vedotin-tftv, or “TV”) in second-line patients with recurrent or metastatic cervical cancer who previously progressed after chemotherapy rather than PD-(L)1 systemic therapy, the companies said in a release.

Dave Lennon, former president of Novartis Gene Therapies

Zol­gens­ma patent spat brews be­tween No­var­tis and Re­genxbio as top No­var­tis gene ther­a­py ex­ec de­parts

Regenxbio, a small licensor of gene therapy viral vectors spun out from the University of Pennsylvania, is now finding itself in the middle of some major league patent fights.

In addition to a patent suit with Sarepta Therapeutics from last September, Novartis, is now trying to push its smaller partner out of the way. The Swiss biopharma licensed Regenxbio’s AAV9 vector for its $2.1 million spinal muscular atrophy therapy Zolgensma.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 117,700+ biopharma pros reading Endpoints daily — and it's free.

Time for round 2: Il­lu­mi­na-backed VC snags $325M for its next fund

Illumina Ventures closed off its second investment fund with a total commitment of $325 million, offering fresh fuel to back a slate of startups that have already included a smorgasbord of companies, covering everything from diagnostics to biotech drug development and genomics.

Fund II brings the total investment under Illumina Ventures’ oversight to $560 million, which has been focused on early-stage companies. And it has a transatlantic portfolio that includes SQZ, Twist and Encoded Therapeutics.

Volker Wagner (L) and Jeff Legos

As Bay­er, No­var­tis stack up their ra­dio­phar­ma­ceu­ti­cal da­ta at #ES­MO21, a key de­bate takes shape

Ten years ago, a small Norwegian biotech by the name of Algeta showed up at ESMO — then the European Multidisciplinary Cancer Conference 2011 — and declared that its Bayer-partnered targeted radionuclide therapy, radium-223 chloride, boosted the overall survival of castration-resistant prostate cancer patients with symptomatic bone metastases.

In a Phase III study dubbed ALSYMPCA, patients who were treated with radium-223 chloride lived a median of 14 months compared to 11.2 months. The FDA would stamp an approval on it based on those data two years later, after Bayer snapped up Algeta and christened the drug Xofigo.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 117,700+ biopharma pros reading Endpoints daily — and it's free.